title: [Photodynamic therapy for subretinal neovascular membranes. Communication 2. Results of treatment for complicated myopia].
abstract: The efficiency of photodynamic therapy (PDT) versus drug therapy was evaluated in patients with subretinal neovascular membranes (SNM) in complicated myopia (CM). Photosens (aluminum phthalocyanine) was intravenously injected in a dose of 0.05 mg/kg. The irradiation conditions were as follows: a session was carried out, using a laser at a wavelength of 675 nm, in an exposure light dose of 120 J/cm2. The number of sessions ranged from 3 to 5 a week, depending on the clinical picture of SNM. The total light dose was not greater than 500 J/cm2. Twelve months after drug therapy and a course of PDT, reduced visual acuity was observed in 50% and only 20.8% of cases, respectively. Stabilization or increase of visual functions occurred in the remaining patients receiving a course of PDT.
authors.forename: S E
authors.initials: SE
authors.lastname: Avetisov
authors.forename: M V
authors.initials: MV
authors.lastname: Budzinskaia
authors.forename: T N
authors.initials: TN
authors.lastname: Kiseleva
authors.forename: E E
authors.initials: EE
authors.lastname: Kazarian
authors.forename: I V
authors.initials: IV
authors.lastname: Gurova
authors.forename: T V
authors.initials: TV
authors.lastname: Smirnova
authors.forename: I V
authors.initials: IV
authors.lastname: Shcheglova
authors.forename: E A
authors.initials: EA
authors.lastname: Privivkova
authors.forename: V B
authors.initials: VB
authors.lastname: Loshchenov
authors.forename: S A
authors.initials: SA
authors.lastname: Shevchik
authors.forename: S G
authors.initials: SG
authors.lastname: Kuz'min
authors.forename: G N
authors.initials: GN
authors.lastname: Vorozhtsov
mesh_terms: D000328:Adult; D004596:Electroretinography; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000627:therapeutic use*; D007275:Injections, Intravenous; D009216:Myopia / Q000150:complications* / Q000503:physiopathology; D009887:Ophthalmoscopy; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D010778:Photochemotherapy / Q000379:methods*; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D012029:Refraction, Ocular; D012160:Retina / Q000473:pathology / Q000503:physiopathology; D015861:Retinal Neovascularization / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome; D014792:Visual Acuity
chemical_list: D007211:Indoles; D009942:Organometallic Compounds; D011838:Radiation-Sensitizing Agents; C048577:aluminum tetrasulfophthalocyanine